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Human narcolepsy-cataplexy, a sleep disorder associated with a centrally mediated hypocretin (orexin) deficiency,
is tightly associated with HLA-DQB1*0602. Few studies have investigated the influence that additional HLA class
II alleles have on susceptibility to this disease. In this work, 1,087 control subjects and 420 narcoleptic subjects
with cataplexy, from three ethnic groups, were HLA typed, and the effects of HLA-DRB1, -DQA1, and -DQB1
were analyzed. As reported elsewhere, almost all narcoleptic subjects were positive for both HLA-DQA1*0102
and -DQB1*0602. A strong predisposing effect was observed in DQB1*0602 homozygotes, across all ethnic groups.
Relative risks for narcolepsy were next calculated for heterozygous DQB1*0602/other HLA class II allelic com-
binations. Nine HLA class II alleles carried in transwith DQB1*0602 were found to influence disease predisposition.
Significantly higher relative risks were observed for heterozygote combinations including DQB1*0301, DQA1*06,
DRB1*04, DRB1*08, DRB1*11, and DRB1*12. Three alleles—DQB1*0601, DQB1*0501, and DQA1*01 (non-
DQA1*0102)—were found to be protective. The genetic contribution of HLA-DQ to narcolepsy susceptibility was
also estimated by use of l statistics. Results indicate that complex HLA-DR and -DQ interactions contribute to
the genetic predisposition to human narcolepsy but that additional susceptibility loci are also most likely involved.
Together with the recent hypocretin discoveries, these findings are consistent with an immunologically mediated
destruction of hypocretin-containing cells in human narcolepsy-cataplexy.
Introduction
Our understanding of the pathophysiology of the sleep
disorder narcolepsy (MIM 161400), a disorder associ-
ated with HLA-DR and -DQ is rapidly emerging. The
gene for an autosomal recessive caninemodel of the sleep
disorder was recently cloned and found to be a receptor
for a neuropeptide system, hypocretin/orexin (Lin et al.
1999). This finding was quickly followed by reports that
preprohypocretin-knockout mice have symptoms similar
to narcolepsy (Chemelli et al. 1999). Finally, human nar-
colepsy-cataplexy is associated with a loss of hypocretin-
containing cells in the perifornical hypothalamus (Pey-
ron et al. 2000; Thannickal et al. 2000) and with
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resulting undetectable CSF hypocretin-1 levels (Nishino
et al. 2000).
In contrast to animal models, human narcolepsy is
not a simple genetic disorder (Honda et al. 1983, 1997;
Mignot 1998) and does not involve highly penetrant
hypocretin-gene mutations (Peyron et al. 2000). Most
human cases of narcolepsy are sporadic and carry the
HLA haplotype DRB1*1501-DQA1*0102-DQB1*0602
(DR2,DQ1) (Honda et al. 1997;Mignot 1998). Familial
cases are the exception rather than the rule, and MZ-
twin reports indicate partial (25%–31%) concordance
(Mignot 1998), suggesting environmental effects on a
specific genetic background.
In spite of the close association that the disease has
with HLA, a direct involvement of the immune system
in narcolepsy has not yet been demonstrated.All attempts
at demonstrating CNS and/or peripheral autoimmunity
in narcolepsy have failed (Matsuki et al. 1988; Carlander
et al; 1993; Mignot et al. 1995). This has led to the
hypothesis that an unknown, nonimmune sleep-control
gene mapping in theHLA region is the direct determinant
of genetic susceptibility and that the HLA-DR and -DQ
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associations are secondary (Matsuki et al. 1988; Carlan-
der et al; 1993; Mignot et al. 1995). This hypothesis is
now believed to be less likely. In African Americans, nar-
colepsy is associated with other DRB1-DQB1*0602 hap-
lotypes such as DRB1*1101-DQA1*0102-DQB1*0602
or DRB1*1503-DQA1*0102-DQB1*0602, suggesting
that DQA1 and DQB1 play a primary role in suscepti-
bility to the disease (Matsuki et al. 1992; Mignot et al.
1994, 1997a, 1997b; Pelin et al. 1998). Microsatellite
and HLA-haplotype analysis also suggest that HLA-
DQB1*0602 has a direct involvement in susceptibility to
narcolepsy (Mignot et al. 1997b). Finally, extended se-
quencing in the HLA-DQ region has identified no novel
candidate genes (Ellis et al. 1997).
In a recent study, we observed that white Ameri-
can and African American patients homozygous for
HLA-DQB1*0602 have twofold-to-fourfold–higher
risk compared with that in HLA-DQB1*0602 het-
erozygotes (Pelin et al. 1998). This observation led us
to speculate that HLA alleles other than HLA-
DQB1*0602 might have additional effects in influenc-
ing the susceptibility to develop narcolepsy. To test this
hypothesis, narcoleptic and control subjects from three
ethnic groups (African Americans, white Americans,
and Japanese) were HLA-DR and -DQ typed, and the
effect of HLA alleles other than HLA-DQB1*0602 was
analyzed. This study led us to confirm a strong effect
of DQB1*0602 homozygosity and to identify other
HLA class II alleles as secondary narcolepsy-suscepti-
bility alleles (for sequences of HLA class II alleles, see
the IMGT/HLA Sequence Database). We also used the
derived relative risks for the various genotypes, to es-
timate the total recurrence-risk ratio attributable to
HLA (Risch 1987).
Subjects and Methods
Subjects
A total of 420 patients and 1,087 control subjects
were included in this study. All narcoleptic patients had
definite cataplexy, the hallmark of the disorder. Ethnicity
was defined as Japanese (both parents of Japanese ori-
gin), African Americans (both parents African Ameri-
cans), or white Americans (both parents white Ameri-
cans). Japanese narcoleptic patients either were recruited
at Seiwa Hospital (by Y.H.; ) or were Japanesenp 100
American patients ( ) with all four grandparentsnp 5
born in Japan. White American ( ), Japanesenp 238
( ), and African American ( ) patients werenp 5 np 77
recruited at Stanford University. Either Y.H. (for all but
five Japanese American subjects) or E.M. reviewed all
clinical files before the subjects were included in the
study. HLA-typed Japanese control subjects ( )np 698
were kindly provided by Akinori Kimura (Tokyo) and
have been described elsewhere (Lin et al. 1997). HLA-
typed African American ( ) and white Americannp 243
( ) control subjects were mostly provided by M.np 146
S. Leffell (Baltimore) and S. Hsu (Philadelphia), respec-
tively, with a few subjects recruited at Stanford.
HLA Typing
HLA-DRB1 and -DQB1 loci were typed in several
laboratories over a period of several years. All narco-
lepsy samples were HLA-DRB1 typed and HLA-DQB1
typed at Stanford, by either Innotype reverse-dot-blot
kits used according to the manufacturer’s recommen-
dations (Robbins Scientific, Sunnyvale, CA USA) or a
sequence-specific oligonucleotide probe–enzyme-linked
immunosorbent assay (SSOP-ELISA) technique (Krish-
naswamy et al. 2000). Most control subjects were high-
resolution DRB1 typed and DQB1 typed either in Japan
or at Stanford, by PCR oligotyping techniques described
by Yasunaga et al. (1996). Intermediate- to high-level
typing resolution for DRB1 and DQB1 was obtained in
all cases. Not all known DRB1 and DQB1 alleles were
distinguished by this method, and resolution is reported
at the lowest level common to all the techniques used;
for example, DQB1*0602 was not distinguished from
the rare DQB1*0611 subtype. Japanese control samples
were HLA-DQA1 typed in Japan, as described elsewhere
(Yasunaga et al. 1996). Intermediate-resolution DQA1
typing was performed on all narcolepsy samples and
most control samples, by PCR oligotyping techniques,
at the American Red Cross National Histocompatibility
Laboratory in Baltimore (Fernandez-Vina et al. 1991).
HLA Class II Haplotype Assignments
Subjects were not phased because of a lack of relatives.
Two-locus (DQA1-DQB1) and three-locus (DRB1-
DQA1-DQB1) haplotypes were assigned to all subjects
on the basis of known associations as described by Fer-
nandez-Vina et al. (1991) and Lin et al. (1997). To do
so, (i) it was assumed that the DRB1, DQA1, and DQB1
loci have no blanks, and, on the basis of this assumption,
when a single HLA allele was found, the individual was
considered to be homozygous for that allele; (ii) in the
assignment of haplotypes, priority was given both to
combinations known to exist in homozygous B-cell lines
or families and, in the analysis of unrelated individuals,
to alleles having 100% associations; and (iii) rare as-
sociations were accepted when the other complementary
haplotypes were well defined (i.e., fitted criteria ii). The
frequency of the DRB1-DQA1-DQB1 haplotypes and of
the class II alleles of interest was then compared in the
control group and the affected group, by x2 test.
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Analysis of the Effects of HLA Alleles Located in trans
of DQB1*0602
The goal of this analysis was to determine whether
HLA alleles other than DQB1*0602 modulate narco-
lepsy susceptibility across ethnic groups. This analysis
was performed for individual alleles and for two- and
three-locus haplotypes. We first compared the relative
risks of various DRB1*X-DQA1*0102-DQB1*0602
haplotypes in the three populations. Relative risks were
estimated by odds ratios (ORs), with DRB1*15-
DQA1*0102-DQB1*0602 homozygotes being used as
the referent. This analysis allowed us to expand on the
observation that DQB1*0602 is the major susceptibility
allele and to confirm that DQB1*0602 homozygosity
greatly increases narcolepsy susceptibility across all eth-
nic groups. For this analysis, we used the Hardy-Wein-
berg (HW) expected genotype frequencies for the control
subjects, rather than the actual observed genotype
counts, to obtain greater precision in the OR estimates.
The frequencies of various HLA alleles (DQB1,
DQA1, and DRB1) located trans to HLA-DQB1*0602
were next compared in narcoleptic subjects versus con-
trol subjects. To do this, we calculated ORs for the alleles
carried on the non-DQB1*0602 chromosome, sepa-
rately for the Japanese, white American, and African
American samples. The ORs were then summarized into
a single estimate across the three ethnicities, by theMan-
tel-Haenszel (MH)OR estimate, and the significancewas
determined by an MH x2 test.
To assess the heterogeneity of the OR estimates for
each allele, we used the MH OR to estimate the number
of observations expected to fall within the four cells of
each table, given the total number of patients’ alleles
and of control alleles and the number of alleles of each
type (i.e., the 2#2 table margins). This was done for
each of the three ethnicities. A x2 statistic was then de-
rived for each of these three tables, and the three sta-
tistics were summed. The total x2 distribution has 2 df
(i.e., three independent tables minus one parameter es-
timate [i.e., OR]). The significance of this homogeneity
test was then assessed by comparison of the derived total
versus a 2-df x2 distribution. This test was performed
only when all margin totals for a given table were at
least five. In most cases, all three of the populations met
this criterion, leading to a homogeneity x2 test with 2
df. In a few cases, only two of the three populations met
this criterion. In these cases, we performed the goodness-
of-fit test on these two populations, with the resulting
homogeneity statistics being x2 with only 1 df. For those
cases in which only one table met the criterion for anal-
ysis, no homogeneity test was performed. In total, 26
alleles were subjected to homogeneity testing.
To assess the significance of departure from 1.0, for
the estimated MH ORs for each locus, we employed a
sequential procedure. At step 1, for a locus with n alleles,
we examined the MH x2 for each of the n alleles tested.
A nominal P value was determined for the maximum x2
value. To evaluate the significance of the maximum x2,
we calculated , which represents the∗ nP p 1 (1 P)
probability that the maximum of n x2 statistics has a
value as large as or greater than that observed, when
the n statistics are assumed to be independent. In this
case, the n statistics are modestly negatively correlated,
so this derived P value is anticonservative. A more con-
servative derived P value is the Bonferonni correction,
, which, in this case, is conservative. However,P p nPc
for small values of P, P* and Pc are very similar to one
another, and we therefore, in general, employed the con-
servative Pc value.
If an allele was found to be significant (i.e., P ! .05c
for the maximum of n alleles), it was removed from the
analysis, and the process then was repeated. This pro-
cedure was iterated until no more alleles were found to
be significant. The importance of doing this stepwise
procedure is that, if one allele is strongly associated (pos-
itively or negatively) with disease risk, then all other
alleles also will appear to deviate from an OR of 1.0
and may be significant as well. This stepwise procedure
allowed us to evaluate the effects of alleles after taking
into account the background influence of alleles that
were more strongly associated.
In a last analysis, the relative risks for various DRB1-
DQA1-DQB1 haplotype combinations were calculated.
This procedure was performed only for haplotypes car-
rying the DRB1, DQB1, and DQA1 alleles previously
identified, on the basis of the stringent criteria detailed
above, as significantly modifying disease susceptibility.
The goal of this analysis was to examine the effects of
various HLA alleles within the context of each extended
haplotype. For this analysis, predisposing haplotypes
were ranked by relative risks, compared with reference
DRB1*15-DQA1*0102-DQB1*0602 homozygotes in
the three ethnic groups.
Analysis of Patients Who Are Negative for HLA-
DQB1*0602
To assess whether HLA alleles other thanDQB1*0602
are associated with narcolepsy in patients without
DQB1*0602, we first calculated ORs for the 25 white
American non-DQB1*0602 patients (50 chromosomes),
comparing them with the same white American controls
as had been used previously. For the DQB1*0602 het-
erozygotes, we evaluated the same alleles for loci DQB1,
DQA1, and DRB1 as had been used above, using the
same sequential procedure. This led us to estimate ORs
for individual HLA class II alleles and to calculate their
statistical significance. Second, we tested whether the
pattern of ORs for these alleles was similar to that ob-
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tained in DQB1*0602 heterozygotes, using the follow-
ing analysis. For each of the three loci, we calculated
the mean and variance of the log ORs across all alleles
at that locus, as seen in the DQB1*0602 heterozygotes
and in non-DQB1*0602 patients. The log ORs were
used because these are more normally distributed than
are the untransformed ORs. We then estimated whether
the pattern of ORs for all alleles was correlated between
the non-DQB1*0602 white Americans and three differ-
ent DQB1*0602-heterozygote groups: white Americans,
all three ethnic groups combined, and Japanese and Af-
rican Americans combined. For the latter two groups,
MHORswere used. The comparisons with the nonwhite
groups were performed to exclude the possibility of a
spurious correlation due to differential allele frequencies
in white American control subjects and narcoleptic sub-
jects—which could result, for example, from differential
recruitments within the United States. Finally, to analyze
the three loci together, we also calculated a single cor-
relation coefficient combining the log ORs for all three
loci together, as a single group. The significance of the
estimated correlation r versus the hypothesis H0: rp
was tested by creating the Fisher Z-transform:0 Zp
, where r is the estimated cor-1 [log(1 r) log(1 r)]2
relation, and the standard error of Z is given by
, where n is the number of observations (al-1/ n 3
leles). In this case, because only of the n ORs atn 1
a given locus are independent, we used the formula
for the standard error when there were n1/ n 4
alleles.
Estimation of the Genetic Contribution of DQ to
Narcolepsy Susceptibility
The main effect observed in this study was that of
HLA-DQB1. We thus estimated l for HLA-DQ in the
three ethnic groups, using established DQB1 allele fre-
quencies and MH OR estimates across the three ethnic
groups. Alleles included in the calculations were
DQB1*0602 and all other significant DQB1 alleles in
heterozygote combinations. Calculations were per-
formed as described by Risch (1987).
Results
HLA-DQB1*0602: The Major Narcolepsy-Susceptibility
Allele in Three Ethnic Groups
HLA-DRB1, -DQA1, and -DQB1 allele frequencies
are reported in table 1. As previously reported,
DRB1*15, DQA1*0102, and DQB1*0602 frequen-
cies were significantly increased in narcolepsy, across
all three ethnic groups. DRB1*11 was also significantly
increased in African Americans. DRB1*15 and
DQB1*0602 were both similarly associated with nar-
colepsy in Japanese and white American subjects. In Af-
rican Americans, DQB1*0602 was more strongly as-
sociated with narcolepsy than was HLA-DRB1*15.
Predisposing Effects of Various HLA–DRB1*X-
DQA1*0102-DQB1*0602 Haplotypes
Relative risks for various DRB1-DQA1-DQB1*0602
haplotypes are reported in table 2. The major goal of this
analysis was to compare relative risks for DRB1*11-
DQA1*0102-DQB1*0602, a classical African haplo-
type, with that of DRB1*15-DQA1*0102-DQB1*0602.
In this analysis, among African Americans both haplo-
types were found to predispose similarly to narcolepsy,
but an approximately twofold-higher relative risk was
observed for DRB1*11-associated haplotypes in hetero-
zygotes ( ; , ) and in homo-2ORp 2.1 x p 2.96 Pp .08
zygotes (not significant). The rare haplotypes DRB1*03-
DQA1*0102-DQB1*0602, DRB1*08-DQA1*0102-
DQB1*0602, and DRB1*12-DQA1*0102-DQB1*0602
were also found in several narcoleptic patients. As had
been reported in previous studies of white Americans
and African Americans, DQB1*0602 homozygosity
(Pelin et al. 1998) was also found to dramatically
increase relative risk, independently of HLA-DRB1.
The effect was most striking in Japanese subjects, in
whom DRB1*1501-DQA1*0102-DQB1*0602 homo-
zygotes represented 15.2% of the narcolepsy popula-
tion, compared with 0.4% in the general population,
for this haplotype. ORs for DRB1*1501-DQA1*0102-
DQB1*0602 heterozygotes versus homozygotes were
∼0.2 (table 2), across all three ethnic groups.
Analysis of HLA-DQB1*0602 Heterozygotes
ORs calculated for non-DQB1*0602 alleles located
trans to the predisposing DQB1*0602 haplotype are re-
ported in tables 3–5. At locus DQB1, three alleles were
deemed significant (table 3). The allele with the strongest
effect was DQB1*0301, with an MH OR of 2.09
( , ). DQB1*0602/DQB1*03012x p 23.86 P p .000013c
was found to confer increased risk of development of
narcolepsy, across all three ethnic groups. The allele
with the next-strongest effect was DQB1*0601, which
had an OR of 0.34 ( , ; this value2x p 8.65 P p .04c
was obtained after DQB1*0301 was removed from
the analysis). Note that DQB1*0601 was found at high
frequency primarily in the Japanese population.
DQB1*0601/DQB1*0602 heterozygotes were thus
found to confer decreased risk of development of nar-
colepsy. The last allele indicating significance was
DQB1*0501, with an OR of 0.51 ( ,2x p 7.07 P pc
). Although this test showed only borderline signifi-.08
cance after correction, at this stage of analysis there were
three alleles giving nominal P values !.05, whereas only
would be expected. Thus, it is likely that11(.05)p .55
this allele is also negatively associated with narcolepsy.
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Table 1
HLA-DRB1*, -DQA1*, and -DQB1* Allele Frequencies in Three Ethnic Groups
ALLELE(S)
NO. (%) IN
MH x2 FOR ALL
THREE GROUPS
Japanese White Americans African Americans
Narcoleptic Control Narcoleptic Control Narcoleptic Control
Total 210 1,396 476 292 154 486
DRB1*:
01 0 (.00) 100 (7.16) 17 (3.57) 30 (10.27) 2 (1.30) 34 (7.00) 37.21†††††
03 0 (.00) 7 (.50) 24 (5.04) 43 (14.73) 11 (7.14) 54 (11.11) 20.56††††
04 32 (15.24) 328 (23.50) 48 (10.08) 28 (9.59) 3 (1.95) 31 (6.38) 6.96††
07 0 (.00) 3 (.21) 39 (8.19) 42 (14.38) 8 (5.19) 58 (11.93) 13.42†††
08 9 (4.29) 182 (13.04) 12 (2.52) 6 (2.05) 9 (5.84) 24 (4.94) 8.62††
09 9 (4.29) 214 (15.33) 0 (.00) 2 (.68) 3 (1.95) 22 (4.53) 22.32††††
10 0 (.00) 5 (.36) 2 (.42) 6 (2.05) 0 (.00) 10 (2.06) 8.55††
11 7 (3.33) 29 (2.08) 32 (6.72) 30 (10.27) 34 (22.08) 58 (11.93)
12 12 (5.71) 61 (4.37) 5 (1.05) 3 (1.03) 8 (5.19) 21 (4.32)
13 10 (4.76) 107 (7.66) 33 (6.93) 42 (14.38) 14 (9.09) 80 (16.46) 17.3†††
14 4 (1.90) 91 (6.52) 5 (1.05) 13 (4.45) 1 (.65) 11 (2.26) 16.46†††
15 126 (60.00) 261 (18.70) 256 (53.78) 41 (14.04) 60 (38.96) 75 (15.43) 318.80†††††
16 1 (.48) 8 (.57) 3 (.63) 6 (2.05) 1 (.65) 8 (1.65) 4.69†
DQA1*:
01 13 (6.19) 462 (33.09) 26 (5.46) 65 (22.26) 8 (5.19) 105 (21.60) 131.65†††††
0102 130 (61.90) 199 (14.26) 280 (58.82) 71 (24.32) 99 (64.29) 129 (26.54) 368.86†††††
02 0 (.00) 3 (.21) 39 (8.19) 42 (14.38) 12 (7.79) 58 (11.93) 9.21††
03 45 (21.43) 576 (41.26) 51 (10.71) 28 (9.59) 6 (3.90) 66 (13.58) 28.85†††††
0401 3 (1.43) 23 (1.65) 9 (1.89) 5 (1.71) 5 (3.25) 39 (8.02)
05 12 (5.71) 115 (8.24) 71 (14.92) 80 (27.40) 24 (15.58) 88 (18.11) 15.44†††
0601 7 (3.33) 18 (1.29) 0 (.00) 1 (.34) 0 (.00) 1 (.21)
DQB1*:
02 0 (.00) 10 (.72) 53 (11.13) 75 (25.68) 23 (14.94) 108 (22.22) 28.83†††††
0301 21 (10.00) 145 (10.39) 71 (14.92) 48 (16.44) 17 (11.04) 85 (17.49)
0302 11 (5.24) 131 (9.38) 27 (5.67) 16 (5.48) 3 (1.95) 23 (4.73)
0303 10 (4.76) 220 (15.76) 8 (1.68) 12 (4.11) 0 (.00) 8 (1.65) 24.49††††
0304 0 (.00) 0 (.00) 1 (.21) 0 (.00) 0 (.00) 0 (.00)
0401 20 (9.52) 187 (13.40) 0 (.00) 0 (.00) 0 (.00) 0 (.00)
0402 5 (2.38) 42 (3.01) 10 (2.10) 5 (1.71) 4 (2.60) 28 (5.76)
0501 2 (.95) 105 (7.52) 19 (3.99) 36 (12.33) 7 (4.55) 76 (15.64) 43.80†††††
0502 2 (.95) 27 (1.93) 4 (.84) 6 (2.05) 1 (.65) 12 (2.47) 4.74†
0503 2 (.95) 36 (2.58) 2 (.42) 13 (4.45) 1 (.65) 11 (2.26) 15.00†††
0601 8 (3.81) 297 (21.28) 0 (.00) 4 (1.37) 0 (.00) 4 (.82) 41.92†††††
0602 121 (57.62) 90 (6.45) 255 (53.57) 37 (12.67) 91 (59.09) 89 (18.31) 530.53†††††
0603 0 (.00) 7 (.50) 5 (1.05) 15 (5.14) 2 (1.30) 19 (3.91) 14.18†††
0604 7 (3.33) 91 (6.52) 19 (3.99) 20 (6.85) 3 (1.95) 15 (3.09) 6.77††
0605 / 0609 1 (.48) 8 (.57) 2 (.42) 5 (1.71) 2 (1.30) 8 (1.65)
† .P ! .05
†† .P ! .01
††† .P ! .001
†††† .P ! .0001
††††† .P ! .000001
DQA1 ORs calculated for the three ethnic groups are
reported in table 4. The strongest effect, a protective
effect, was observed for allele DQA1*01, a broad spec-
ificity encompassing all DQA1*01 alleles except
DQA1*0102 (e.g., alleles DQA1*0101, DQA1*0103,
DQA1*0104, and DQA1*0105). The OR obtained was
0.33 ( , ). After allele DQA1*012x p 36.32 P p .00001c
was removed from the analysis, DQA1*06, primarily a
Japanese allele, was found to be significant, with an OR
of 3.23 ( , ). No other DQA1 alleles2x p 8.39 P p .02c
were found to be significant.
DRB1 ORs calculated for the three ethnic groups are
reported in table 5. The most significant allele was
DRB1*04, with an OR of 1.92 ( ,2x p 14.49 P pc
). After DRB1*04 was removed from the analysis,.007
allele DRB1*12 was found to be significant, with an OR
of 2.84 ( , ). The next significant2x p 15.30 P p .0008c
allele was DRB1*11, with an OR of 2.00 ( ,2x p 11.39
Table 2
ORs for Various DRB1*X-DQA1*0102-DQB1*0602 Combinations in Three Ethnic Groups
HAPLOTYPE 1 / HAPLOTYPE 2
JAPANESE WHITE AMERICANS AFRICAN AMERICANS
ALL THREE
GROUPS
No. (%) in No. (%) in
OR
No. (%) in
OR
MH
OR MH x2
Narcoleptic
( )np 105
Control
( )np 698
HW Adjusted
( )np 698 OR
Narcoleptic
( )np 238
Control
( )np 146
HW Adjusted
( )np 146
Narcoleptic
( )np 77
Control
( )np 243
HW Adjusted
( )np 243
15-0102-0602 / 15-0102-0602 16 (15.2) 5 (.7) 3 (.4) 1.00 43 (18.1) 3 (2.1) 2 (1.6) 1.00 11 (14.3) 8 (3.3) 4 (1.8) 1.00 1.00 Reference
15-0102-0602 / any haplotype 89 (84.8) 80 (11.5) 84 (12.1) .20†† 169 (71.0) 31 (21.2) 32 (21.1) .25† 31 (40.3) 47 (19.3) 53 (21.9) .21†† .22 17.73†††
03-01-0602 / 15-0102-0602 0 1 (.4) 0 (.1) .00
03-01-0602 / any haplotype 0 0 1 (.3) .00
03-0102-0602 / any haplotype 1 (.4) 0 0  0 1 (.4) 1 (.3) .00
08-0102-0602 / 15-0102-0602 1 (1.3) 0 (.0) 0 (.1) 
08-0102-0602 / any haplotype 3 (3.9) 1 (.4) 1 (.3) 1.09
11-0102-0602 / 11-0102-0602 2 (2.6) 1 (.4) 0 (.1) 
11-0102-0602 / 15-0102-0602 5 (6.5) 0 2 (.9) .91
11-0102-0602 / any haplotype 16 (20.8) 14 (5.8) 13 (5.4) .45
12-0102-0602 / any haplotype 2 (2.6) 0 0 
13-01-0602 / any haplotype 0 1 (.4) 2 (1.0) .00
13-0102-0602 / any haplotype 0 1 (.4) 1 (.3) .00
15-02-0602 / any haplotype 0 1 (.4) 1 (.3) .00
16-0102-0602 / any haplotype 1 (1.3) 0 0 
Any / any 0 613 (87.8) 611 (87.5) .00 25 (10.5) 112 (76.7) 111 (76.3) .01 5 (6.5) 167 (68.7) 162 (66.7) .01††††† .01 275.75†††††
Rare 0102-0602 combinations 0 0 1 (.5) .00
† .P ! .05
†† .P ! .01
††† .P ! .001
††††† .P ! .000001
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Table 3
ORs, Mantel-Haenszel ORs, and x2 for DQB1 Alleles in Three Ethnic Groups
DQB1
ALLELE
JAPANESE WHITE AMERICANS AFRICAN AMERICANS
No.
OR
No. No.
OR
ALL THREE GROUPS
Narcoleptic
( )np 89
Control
( )np 1,306
Narcoleptic
( )np 170
Control
( )np 255 OR
Narcoleptic
( )np 53
Control
( )np 397 MH OR MH x2
02 0 10 .00 39 75 .71 17 108 1.26 .85 .82
0301 21 145 2.48††† 55 48 2.06†† 17 85 1.73 2.09 23.86††††
0302 11 131 1.26 22 16 2.22† 2 23 .64 1.50 3.30
0303 10 220 .62 8 12 1.00 0 8 .00 .69 1.87
0401 20 187 1.73† 0 0 … 0 0 … 1.73 4.38†
0402 5 42 1.79 8 5 2.47 3 28 .79 1.55 1.97
0501 2 105 .26† 13 36 .50† 6 76 .54 .46 9.76††
0502 2 27 1.09 4 6 1.00 0 12 .00 .77 .30
0503 2 36 .81 1 13 .11† 1 11 .67 .37 4.42†
0601 8 297 .33†† 0 4 .00 0 4 .00 .30 11.73†††
0603 0 7 .00 3 15 .29† 2 19 .78 .40 3.94†
0604 7 91 1.14 15 20 1.14 3 15 1.53 1.18 .46
0609 1 8 1.84 2 5 .60 2 8 1.91 1.13 .06
† .P ! .05
†† .P ! .01
††† .P ! .001
†††† .P ! .0001
). The last significant allele was DRB1*08, withP p .06c
an OR of 2.17 ( , ). In this case, all2x p 7.42 P p .046c
four significant alleles were predisposing.
We also tested whether any alleles demonstrated nom-
inally significant ( ) heterogeneity among the threeP ! .05
ethnicities. Only one allele, DQA1*03, demonstrated
such an effect, with ORs of 1.39. 2.89, and 0.42 in
Japanese, white Americans, and African Americans, re-
spectively. The x2 for this allele was 11.87, which cor-
responds to ; however, given the fact that 26Pp .005
such tests were performed, it is not so unlikely that one
case with a P value at this level will be observed. Thus,
overall, we have little evidence of heterogeneity across
populations, for the derived ORs.
In conclusion, a total of nine alleles were found to be
significantly associated with either increased or de-
creased risk of narcolepsy in DQB1*0602 heterozygotes.
At this stage, we also recalculated the ORs for all sig-
nificant alleles at that locus, using, as the reference, all
nonsignificant alleles combined. The final ORs for each
of the nine alleles in this analysis are given in table 6.
Six of the nine alleles are predisposing, and three are
protective.
Predisposing Effects of Various Three-Locus Haplotypes
When Located trans to a DQA1*0102-DQB1*0602
Haplotype
To examine in more detail the pattern of linkage dis-
equilibrium for the identified susceptibility alleles, we
next examined relative risks for various DRB1-DQA1-
DQB1 haplotype combinations (table 7) carrying these
alleles. For this analysis, predisposing haplotypes were
ranked by relative risks versus reference DRB1*15-
DQA1*0102-DQB1*0602 homozygotes in the three
ethnic groups. The analysis displayed in table 7 included
only those haplotype combinations with a frequency
11.3% in either narcoleptic subjects or HW-derived con-
trol subjects.
In Japanese subjects, the most significant effect
was observed in DRB1*15-DQA1*0102-DQB1*0602/
DRB1*12-DQA1*06-DQB1*0301. The effect of this
Asian-specific haplotype could not be verified in oth-
er ethnic groups. Besides effects associated with
DQB1*0602 homozygosity, other significant risk in-
creases were observed for DRB1*11-, DRB1*12-,
DQB1*0301-, DRB1*08-, and DRB1*04-carrying hap-
lotypes, in agreement with the analysis performed for
individual loci. It is noteworthy that several DRB1*04
haplotypes with distinct DQB1 alleles ranked high in
susceptibility, suggesting a primary effect of DRB1*04
in some cases. Similar findings were observed for
DRB1*08. In contrast, it was more difficult to differ-
entiate DRB1*11/DRB1*12 effects from a potential
DQB1*0301 effect; these alleles are almost exclusively
associated. The least-susceptible combinations were
those including DQB1*0601 and DQB1*0501. The
protective effect of DQB1*0601 is remarkable, since
this allele is frequently associated with DRB1*15 (table
3). It is noteworthy that the DRB1*08-DQA1*01-
DQB1*0601 was also protective, suggesting a primary
effect of DQB1*0601.
In white Americans, similar effects were observed,
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Table 4
ORs, Mantel-Haenszel ORs, and x2 for DQA1 Alleles in Three Ethnic Groups
DQB1
ALLELE
JAPANESE WHITE AMERICANS AFRICAN AMERICANS
No.
OR
No.
OR
No.
OR
ALL THREE GROUPS
Narcoleptic
( )np 80
Control
( )np 1,197
Narcoleptic
( )np 149
Control
( )np 221
Narcoleptic
( )np 46
Control
( )np 354 MH OR MH x2
01 13 462 .31††† 17 65 .31††† 7 105 .43† .33 36.32†††††
02 0 3 .00 28 42 .99 9 58 1.24 1.05 .04
03 45 576 1.39 44 28 2.89††† 4 66 .42 1.56 7.53††
04 3 23 1.99 7 5 2.13 4 39 .77 1.35 .82
05 12 115 1.66 53 80 .97 22 88 2.77†† 1.40 4.65†
06 7 18 6.28†††† 0 1 .00 0 1 .00 4.18 13.56†††
† .P ! .05
†† .P ! .01
††† .P ! .001
†††† .P ! .0001
††††† .P ! .000001
with DRB1*08-, DRB1*04-, DRB1*11-, DQA1*0501-,
and DQB1*0301-carrying haplotypes increasing suscep-
tibility, whereas the DRB1*01-DQA1*01-DQB1*0501
haplotype was rather protective. Results were more dif-
ficult to interpret in African Americans, because of both
the smaller sample size and the increased HLA-haplo-
type diversity. Consistent with the results obtained in
other ethnic groups, DRB1*11- and DQB1*0301-car-
rying haplotypes were generally associated with in-
creased susceptibility, whereas DRB1*01-DQA1*01-
DQB1*0501 reduced relative risks. DRB1*13-asso-
ciated haplotypes were also overrepresented. It is
noteworthy that ORs for DRB1*04-DQA1*03-
DQB1*0302 did not rank high in this ethnic group.
Analysis of White American Patients without HLA-
DQB1*0602
ORs for the 25 white American patients were esti-
mated and compared with those in the white American
control subjects. Other ethnic groups were not studied,
because of the small numbers of non-DQB1*0602 sub-
jects. Results are reported in table 8. Interestingly,
DQB1*0301 wasmarginally increased in this group (OR
1.6; , ), but none of the 25 tested al-2x p 4.38 Pp .04
leles met criteria for significance after adjustment for
multiple comparisons. The patterns of ORs reported in
table 8 and in tables 3–5 for, respectively, loci DQB1,
DQA1, and DRB1, were also strikingly similar; for ex-
ample, at DQB1, of the four alleles that have ORs 11
in table 8, three have ORs 11 in table 3; similarly, of
the four alleles that have ORs !1 in table 8, all four
have ORs !1 in table 3. Similarly, extremely concordant
patterns were observed for loci DQA1 and DRB1.
The concordance was supported by correlation anal-
ysis of the log ORs (table 9). When the white American
DQB1*0602 heterozygotes were used for comparison,
the correlations for each of the three loci were .57-.82
and .61 for all three loci combined ( ). Because ofP ! .01
the potential for an artifactual correlation due to use of
the same control group for calculation of the ORs for
the white American DQB1*0602 heterozygotes and
non-DQB1*0602 cases, we also calculated the correla-
tion in log ORs, with the MH average of the Japanese
and African American ORs as a second comparison; here
again the correlations were quite positive, with the cor-
responding values being .46–.50 and .48, respectively.
Thus, the observed correlation in log ORs is unlikely to
be an artifact of the comparison with thewhiteAmerican
population. Interestingly, the highest correlation was ob-
tained with the MH OR DQB1*0602 heterozygote av-
erage for all three ethnic groups, in which the corre-
sponding values were .66–.73 and .67, respectively. This
likely reflects the greater precision obtained in the OR
estimates when the larger sample of combined ethnicities
is used.
Genetic Contribution of HLA-DR and -DQ to
Narcolepsy Susceptibility
l Values (lS and lO) for HLA-DQ effects were cal-
culated in the three ethnic groups. Only the effects of
the major susceptibility alleles—DQB1*0301,
DQB1*0501, DQB1*0601, and DQB1*0602—were in-
tegrated in the calculation. For this calculation, ORs
were assumed to be the same in all three ethnic groups
(OR for DQB1*0602/DQB1*0602 p 1.00, OR for
DQB1*0602 /DQB1*0301p 0 . 449 , OR fo r
DQB1*0602 /DQB1*0501p 0 . 134 , OR fo r
DQB1*0602/DQB1*0601p 0.066, and OR for
DQB1*0602/DQB1*X p 0.265, with X being any
DQB1 allele other than DQB1*0602, DQB1*0301,
DQB1*0501, or DQB1*0601, and, for DQB1*Y/
DQB1*Yp 0.012, with Y being any DQB1 allele other
694 Am. J. Hum. Genet. 68:686–699, 2001
Table 5
ORs, Mantel-Haenszel ORs, and x2 for DRB1 Alleles in Three Ethnic Groups
DQB1
ALLELE
JAPANESE WHITE AMERICANS AFRICAN AMERICANS
No.
OR
No.
OR
No.
OR
ALL THREE GROUPS
Narcoleptic
( )np 73
Control
( )np 1,122
Narcoleptic
( )np 165
Control
( )np 239
Narcoleptic
( )np 54
Control
( )np 393 MH OR MH x2
01 2 100 .29 12 30 .55 1 34 .20 .41 8.88††
03 0 7 .00 19 43 .59 7 54 .93 .67 2.71
04 32 328 1.89†† 42 28 2.57††† 2 31 .45 1.92 14.49†††
07 0 3 .00 28 42 .96 6 58 .72 .88 .31
08 9 182 .73 8 6 1.98 5 24 1.57 1.08 .08
09 9 214 .60 0 2 .00 2 22 .65 .57 3.02
11 7 29 4.00††† 27 30 1.36 15 58 2.22† 1.87 10.61††
12 12 61 3.42††† 2 3 .97 5 21 1.81 2.41 11.32†††
13 8 107 1.17 25 42 .84 11 80 1.00 .95 .07
14 4 91 .66 2 13 .21† 0 11 .00 .39 5.45†
† .P ! .05
†† .P ! .01
††† .P ! .001
Table 6
Mantel-Haenszel Final ORs for Alleles
Found to Be Significant, Relative to All
Other Alleles Grouped Together
Allele
MH OR for All
Three Groups
DQB1:
0301 1.80
0501 .51
0601 .31
All others 1.00
DQA1:
01 .34
06a 3.23
All others 1.00
DRB1:
04 2.87
08 2.17
11 2.42
12 3.84
All others 1.00
a Found only in Japanese.
than DQB1*0602). The effect of HLA-DQ was l pS
and in Japanese, and3.54 l p 3.18 l p 2.70 l pO S O
in white Americans, and and2.56 l p 2.35 l pS O
in African Americans. Most of the effect was due2.23
to DQB1*0602, with other alleles contributing little to
the l values. The potential additional effects of DRB1
and DQA1 were not computed, since they would result
in only very small changes in l values once the DQB1
effects were taken into account.
Discussion
In this study, we have demonstrated for the first time
that HLA class II alleles other than DQB1*0602 influ-
ence susceptibility to narcolepsy-cataplexy.We also have
extended what previously had been observed in African
Americans and white Americans, by demonstrating that
HLA-DQB1*0602 homozygosity increases susceptibility
in the Japanese population; in fact, the relative risk in
DQB1*0602 homozygotes is extremely high in this pop-
ulation, with 15.2% of patients versus 0.4% of control
subjects having this genotype. Homozygosity in this eth-
nic group increases the risk of development of narcolepsy
approximately fivefold, compared with the risk in het-
erozygotes (OR 0.2; see table 1). In light of the high
prevalence (0.16%) reported for narcolepsy in Japanese,
as many as 6% of DQB1*0602 homozygotes in Japan
could have narcolepsy-cataplexy (in whites, this figure
is only 0.6%). This observation is surprising, since pre-
vious studies had reported no increased risk of DR2
homozygosity in Japanese subjects (Matsuki et al. 1985;
Thomson 1985). Our work now indicates that this effect
was not apparent because the various Asian DR2 hap-
lotypes have dramatically different risks for predispo-
sition to narcolepsy. In Japanese, the most frequent DR2
haplotype is theDRB1*1502-DQA1*0103-DQB1*0601,
a haplotype that we here found to be protective. Low-
resolution DR2 homozygotes in this ethnic group thus
included both DRB1*1501-DQA1*0102-DQB1*0602
homozygotes at increased risk and DRB1*1502-
DQA1*0103-DQB1*0601, a combination reduced in
frequency, with little effect on overall DR2 homozygos-
ity in narcolepsy.
The observation that DQB1*0602 homozygosity in-
creases susceptibility to narcolepsy led us to explore
whether other HLA class II alleles alsomodulate relative
risks. We first evaluated the effect that various DR al-
leles have on a common DQ background, by comparing
relative risks for known DRB1*X-DQA1*0102-
Table 7
DR15-DQA1*0102-DQB1*0602 Haplotype Combinations in Three Ethnic Groups
HAPLOTYPE 1 / HAPLOTYPE 2
NO. (%)
MH OR
RELATIVE
RISKaNarcoleptic Control HW
Japanese
( )np 105 ( )np 698 ( )np 698
15-0102-0602 / 12-0601-0301 7 (6.7) 1 (.1) 1 (.2) 41.5††††† 1.094
15-0102-0602 / 15-0102-0602 16 (15.2) 5 (.7) 3 (.4) 43.1††††† 1.000
15-0102-0602 / 11-05-0301 7 (6.7) 0 2 (.2) 31.1††††† .788
15-0102-0602 / 08-0401-0402 3 (2.9) 1 (.1) 1 (.1) 20.5†† .563
15-0102-0602 / 12-05-0301 4 (3.8) 5 (.7) 2 (.3) 12.5†† .331
15-0102-0102-0602 / 08-03-0302 3 (2.9) 1 (.1) 2 (.2) 12.0†† .325
15-0102-0602 / 04-03-0401 20 (19.0) 11 (1.6) 12 (1.7) 13.5††††† .301
15-0102-0602 / 04-03-0301 2 (1.9) 0 1 (.2) 9.7 .256
15-0102-0602 / 04-03-0302 8 (7.6) 5 (.7) 6 (.8) 9.6††††† .247
15-0102-0602 / 04-03-0402 2 (1.9) 2 (.3) 2 (.2) 8.0 .208
15-0102-0602 / 14-01-0503 2 (1.9) 1 (.1) 2 (.3) 5.9 .156
Other 0102-0602 combinations 21 (20.0) 33 (4.7) 27 (3.9) 6.2††††† .135
15-0102-0602 / 15-01-0601 5 (4.8) 3 (.4) 10 (1.5) 3.3 .088
15-0102-0602 / 08-01-0601 3 (2.9) 12 (1.7) 9 (1.2) 2.4 .063
15-0102-0602 / 01-01-0501 2 (1.9) 5 (.7) 6 (.9) 2.1 .056
Non–0102-0602 / non–0102-0602 0 613 (87.8) 611 (87.5) .0††††† .000
White Americans
( )np 238 ( )np 146 ( )np 146
15-0102-0602 / 08-04-0402 7 (2.9) 0 0 † 
15-0102-0602 / 15-0102-0602 43 (18.1) 3 (2.1) 2 (1.6) 13.8†††† 1.000
15-0102-0602 / 04-03-0301 18 (7.6) 0 1 (.9) 8.7†† .774
15-0102-0602 / 13-05-0301 5 (2.1) 0 0 (.3) 7.8 .717
15-0102-0602 / 04-03-0302 22 (9.2) 5 (3.4) 2 (1.4) 7.3†† .592
15-0102-0602 / 11-05-0301 26 (10.9) 4 (2.7) 4 (2.5) 4.7†† .386
15-0102-0602 / 01-01-0501 12 (5.0) 2 (1.4) 4 (2.6) 2.0 .170
Other 0102-0602 combinations 80 (33.6) 20 (13.7) 22 (15.1) 2.9††† .197
Non–0102-0602 / non–0102-0602 25 (10.5) 112 (76.7) 111 (76.0) .0††††† .012
African Americans
( )np 77 ( )np 243 ( )np 243
11-0102-0602 / 11-0102-0602 2 (2.6) 1 (.4) 0 (.1) 21.6 3.001
11-0102-0602 / 13-05-0301 2 (2.6) 1 (.4) 0 (.2) 12.9 1.600
11-0102-0602 / 11-05-0301 3 (3.9) 1 (.4) 1 (.5) 8.2 1.029
15-0102-0602 / 15-0102-0602 11 (14.3) 8 (3.3) 4 (1.8) 9.3†††† 1.000
15-0102-0602 / 11-0102-0602 5 (6.5) 0 2 (.9) 8.0† .923
15-0102-0602 / 13-0102-0501 2 (2.6) 0 1 (.4) 7.2 .844
15-0102-0602 / 08-05-0301 2 (2.6) 0 1 (.5) 5.4 .657
15-0102-0602 / 11-05-0301 5 (6.5) 6 (2.5) 5 (1.9) 3.5 .422
15-0102-0602 / 12-01-0501 2 (2.6) 2 (.8) 3 (1.0) 2.6 .311
15-0102-0602 / 04-03-0302 2 (2.6) 4 (1.6) 3 (1.2) 2.2 .269
Other 0102-0602 combinations 35 (45.5) 52 (21.4) 57 (23.5) 2.7††† .244
15-0102-0602 / 01-01-0501 1 (1.3) 1 (.4) 5 (1.9) .7 .087
Non–0102-0602 / non–0102-0602 5 (6.5) 167 (68.7) 161 (66.3) .0††††† .012
a Versus 15-0102-0602 homozygosity.
† .P ! .05
†† .P ! .01
††† .P ! .001
†††† .P ! .0001
††††† .P ! .000001
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Table 8
ORs for 25 White American
Patients without the DQB1*0602
Allele
Allele No. Narcoleptic OR
DQB1:
02 14 .89
0301 14 1.60
0302 5 1.60
0303 0 .00
0402 2 2.01
0501 6 .80
0502 2 1.67
0503 1 .37
0603 2 .64
0604 4 .98
Total 50
DQA1:
01 9 .61
02 11 1.41
03 7 1.30
04 2 2.05
05 15 .91
Total 44
DRB1:
01 5 .81
03 4 .42
04 6 1.08
07 11 1.39
08 3 2.59
10 1 .83
11 5 .81
12 3 5.23
13 8 .94
14 1 .37
16 3 2.59
Total 50
Table 9
Correlations of Log ORs between White American Patients
without DQB1*0602 and DQB1*0602 Heterozygotes
LOCUS
CORRELATION OF LOG ORS
FOR HETEROZYGOUS GROUP
(r)
White
Americans
Japanese and
African Americansa
Three
Groupsa
DQB1 .62 .50 .67†
DQA1 .82 .48 .73
DRB1 .57 .46 .66†
All three loci .61†† .48† .67†††
a MH OR estimates were used.
† .P ! .05
†† .P ! .01
††† .P ! .001
DQB1*0602 haplotypes in African Americans (table 2).
This analysis indicated that, although all known
DRB1*X-DQA1*0102-DQB1*0602 haplotypes pre-
dispose to narcolepsy, DRB1 may also influence pre-
disposition. Combinations involving DRB1*11-
DQA1*0102-DQB1*0602 haplotypes, for example,
generally carried higher relative risks than did those
involving the classical DRB1*15-DQA1*0102-
DQB1*0602 haplotype (table 1), although these results
are only suggestive and not statistically significant.
We next explored the effects that various DQB1,
DRB1, and DQA1 alleles located trans to the
DQB1*0602 haplotype have in heterozygotes. The
analysis was performed by first removing, sequentially,
the most significant allele for each locus and then re-
running the analysis on residual frequencies until no
alleles remained significant. The conservative Bonfer-
onni correction was applied to assess statistical signif-
icance. With this procedure, a total of nine alleles were
found to be significant (table 6).
Because of linkage disequilibrium between these al-
leles, we next explored the effect that various DRB1-
DQA1-DQB1 haplotypes have when located trans to a
DQB1*0602 haplotype. This analysis included only
haplotypes containing the nine significant alleles. The
respective frequencies of each heterozygote combination
was ranked by relative risk, with DRB1*15-
DQA1*0102-DQB1*0602 homozygotes used as the
reference (table 7). The most consistent effect was
again the increased risk for DQB1*0301. In all three
ethnic groups, all DQB1*0301-associated haplotypes
ranked high in relative risks. The DQB1*0301 increase
occurred in the context of various HLA haplotypes,
such as DRB1*11-DQA1*05-DQB1*0301, DRB1*12-
DQA1*06-DQB1*0301, DRB1*12-DQA1*05-
DQB1*0301, and DRB1*04-DQA1*03-DQB1*0301,
suggesting a primary DQB1*0301 effect. Further anal-
ysis made it difficult, however, to conclude that all of
the effect is mediated by the DQB1 locus. DRB1*04
and DQB1*08, in particular, may also have strong
effects on susceptibility to narcolepsy. Relative risks
for DRB1*04-DQA1*03-DQB1*0301 and DRB1*04-
DQA1*03-DQB1*0302 were almost identical in white
Americans, suggesting an effect due to DRB1*0401
(which is the typical white DRB1*04). Increased pre-
disposition was also observed with the classical Japa-
nese DRB1*04-DQA1*03-DQB1*0401 haplotype,
possibly as a result of an association with DRB1*0405
and DRB1*0410. A very robust effect of DRB1*04 was
thus observed in white Americans and Japanese but not
in African Americans (table 5), a result that may reflect
increased DRB1*04-DQB1*03 high-resolution allelic
and haplotype diversity in this ethnic group. Similarly,
our DRB1 haplotype analysis suggests the possibility
that other HLA-DR alleles, such as DRB1*11 or
DRB1*12, could have predisposing effects, but, in these
cases, it was impossible to identify whether association
was primarily with DR or with DQB1*0301. DRB1*11
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and DRB1*12 are almost completely associated with
DQB1*0301.
Our initial hypothesis was that our previous report
of increased DQB1*0602 homozygosity in narcolepsy
could be secondary to the protective effects of other
frequent DR-DQ haplotypes. This hypothesis was
largely disproved by the present analysis; rather, we
identified additional predisposing haplotypes. It is note-
worthy, however, that two DQB1 alleles, DQB1*0601
and DQB1*0501, were found to be protective against
narcolepsy in the presence of DQB1*0602 in trans po-
sition. The DQB1*0501 effect was observed across all
three ethnic groups but was difficult to distinguish from
that of the frequently associated DRB1*01 allele. In
contrast, the effect of DQB1*0601 was particularly
convincing, since it was observed in the context of two
frequent DR-DQ Japanese haplotypes, DRB1*08-
DQA1*01-DQB1*0601 (presumably DRB1*0803-
DQA1*01-DQB1*0601) and DRB1*15-DQA1*01-
DQB1*0601 (presumably DRB1*1502-DQA1*0103-
DQB1*0601). It is interesting to note that DQB1*0602
and DQB1*0601 are related subtypes but that one is
predisposing whereas the other is protective. This sug-
gests that there are narcolepsy-relevant differences in
the peptide-binding motifs of these two related
DQB1*06 subtypes.
Our analysis indicates complex HLA-DR and -DQ
effects in human narcolepsy. A computation of the l
values for the identified HLA-DQ effects indicate a
value of only 2–4 in the three ethnic groups, with most
of the effects being attributable to DQB1*0602. The
effect of HLA-DQ was and inl p 3.54 l p 3.18S O
Japanese, and in white Ameri-l p 2.70 l p 2.56S O
cans, and and in African Amer-l p 2.35 l p 2.23S O
icans. These l values are below the relative risks re-
ported in first-degree relatives, indicating that addi-
tional genetic effects are likely to be involved in ge-
netic predisposition to narcolepsy. In whites, several
well-designed prevalence studies and family studies in-
dicate a prevalence of ∼0.02%–0.04% and a 1%–2%
risk in first-degree relatives, indicating a 20–40-fold in-
creased risk (Mignot 1998). In Japanese, the contri-
bution of HLA to overall genetic predisposition might
be higher. Family studies have indicated a 1.1% risk in
first-degree relatives and a population prevalence of
0.16%, yielding a l value of only 6.9 (Honda et al.
1983). It is noteworthy, however, that the prevalence
value may be significantly overestimated in this ethnic
group, leading to artificially low relative risks in rela-
tives. Only one study without polygraphic confirmation
has estimated population prevalence in this ethnic
group, and additional studies would be needed to con-
firm this value. Overall, the l values reported for HLA
in this study are unlikely to fully explain increased fam-
ily clustering in human narcolepsy, even when multiple
susceptibility alleles are taken into account. Other ex-
periments aiming to identify additional susceptibility
loci are ongoing, with suggestive effects of tumor ne-
crosis factor–a polymorphism (Hohjoh et al. 1999) and
genetic linkage to 4q (Nakayama et al. 2000).
The complex pattern of inheritance and the HLA as-
sociation that are observed in human narcolepsy mirror
similar findings reported for other HLA-associated dis-
eases, most of which are autoimmune in nature. The
observations of complex homozygosity and compound-
heterozygote effects are also consistent with HLA-DR
and -DQ being primarily involved in susceptibility to
disease. Recent studies have shown that most cases of
human narcolepsy are associated with a dramatic loss
of hypocretin-containing neurons in the CNS (Peyron
et al. 2000; Thannickal et al. 2000). Most of these cases
are not due to hypocretin-gene mutations (Peyron et al.
2000), yet hypocretin-1 levels are undetectable in the
cerebrospinal fluid (CSF) of most patients (Nishino et
al. 2000). The hypocretin system is a unique target, since
only a small number (∼10,000) of human neurons con-
tain this peptide, and all are discretely localized within
the perifornical hypothalamic region (Peyron et al.
2000). These findings, together with the well-estab-
lished HLA association, suggest that narcolepsy may be
an autoimmune disorder involving the hypocretin
system.
In spite of this thorough analysis, the largest that has
ever been published in the field of narcolepsy research,
several points still must to be clarified. A surprising
result was the observation that the pattern of HLA class
II allele frequencies observed in patients negative for
HLA-DQB1*0602 was highly correlated with that ob-
served in DQB1*0602 heterozygotes (table 9). Current
data, however, indicate that, although most patients
positive for HLA-DQB1*0602 have undetectable CSF
hypocretin levels, most patients negative for HLA-
DQB1*0602 have measurable, if not normal, levels (E.
Mignot, L. Lin, W. Rogers, Y. Honda, X. Qiu, X. Lin,
M. Okun, H. Hohjoh, T. Miki, S. H. Hsu, M. S. Leffell,
F. C. Grumet, M. Fernandez-Vina, M. Honda, N. Risch,
and S. Nishino, unpublished results). The observation
that DQB1*0602-positive and -negative patients show
some clinical differences (e.g., undetectable CSF hypo-
cretin levels vs. detectable levels) but similar features in
their HLA association patterns suggests the presence of
a common pathophysiological mechanism. It is note-
worthy, however, that, in a previous study, we had re-
ported that DQB1*0602 control subjects, who have
normal CSF hypocretin levels (Nishino et al. 2000),
have slightly shorter rapid-eye-movement–sleep latency
(Mignot et al. 1998). Similarly, we also found in a pre-
vious study that HLA-DQB1*0602 homozygotes are
present in increased frequency among narcoleptic pa-
tients without cataplexy (Pelin et al. 1998) yet that these
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subjects also typically do not have undetectable hypo-
cretin CSF levels (E. Mignot, L. Lin, W. Rogers, Y.
Honda, X. Qiu, X. Lin, M. Okun, H. Hohjoh, T. Miki,
S. H. Hsu, M. S. Leffell, F. C. Grumet, M. Fernandez-
Vina, M. Honda, N. Risch, and S. Nishino, unpublished
results). It is therefore possible that genetic variation at
the level of HLA class II influences sleep patterns and
narcolepsy without always resulting in a complete de-
struction of hypocretin-containing cells and undetect-
able CSF levels.
Another limitation of the present study was that
DRB1 effects were difficult to fully evaluate, because of
strong linkage disequilibrium with HLA-DQ, lack of
family data, and lower-resolution typing for this locus.
Recent studies of other HLA-DQ–associated diseases
also now suggest that other HLA-linked polymorphisms
frequently contribute additional susceptibility in pri-
marily HLA class II–associated disorders. Additional
high-resolution DRB1 studies in trio families, as well as
microsatellite studies using markers spanning the HLA
complex, are now underway as part of the 13th Inter-
national Histocompatibility Workshop, in an attempt
to address these two issues.
In conclusion, our study demonstrates that the pat-
tern of HLA association in narcolepsy is as complex as
that observed in other, better-studied HLA-associated
disorders, such as insulin-dependent diabetes mellitus
(Friday et al. 1999; Wen et al. 2000) and multiple scle-
rosis (Allcock et al. 1999; Fogdell-Hahn et al. 2000).
Thus, it is likely but not established that narcolepsy has
an autoimmune basis, as do some other, better-studied
disorders.
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